WEBULL
WebtradeDownload

Medtronic (MDT) Stock Gains Little As Raised Guidance Challenges Caution

Simply Wall St · 4d ago

Medtronic stock edged about 1.5% higher to roughly $92 after earnings, a muted reaction for a company long viewed as a slow and steady medical devices compounder. The headline was far punchier than the share move suggested. First quarter fiscal 2027 adjusted earnings per share landed at $1.45 on $9.8b in revenue, both ahead of expectations, and management lifted full year organic revenue and earnings guidance. For a business often judged on margin quality and durability of growth, that guidance shift is what really challenged the prior, more cautious thesis.

Love Medtronic's steady earnings beat but want more growth excitement than a 1.5% share move offers? Check out the 19 high quality undiscovered gems for stocks that pair solid fundamentals with stronger market momentum.

Q1 2027 Earnings Summary

  • Revenue (Q1 2027 vs. Q1 2026): US$9,756m vs. US$8,578m (up about 13.7%)
  • Net Income (Q1 2027 vs. Q1 2026): US$1,470m vs. US$1,040m (up about 41.3%)
  • Basic EPS (Q1 2027 vs. Q1 2026): US$1.15 vs. US$0.81 (up about 41.6%)
  • Net Profit Margin, trailing 12 months (FY Q1 2027 vs. FY Q1 2026): 13.9% vs. 13.6% (modestly higher)

Prefer clean charts over scrolling through extensive Medtronic financial figures? See the company’s full financial picture with a visual breakdown of its valuation in the company report for Medtronic.

NYSE:MDT Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026
NYSE:MDT Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026

Medtronic Bull Case: Growth Engines Clearing Early Hurdles

Bulls argue Medtronic can shift from “slow and steady” to a higher quality growth profile driven by electrophysiology, renal denervation, robotics and AI enabled surgical ecosystems. Q1 gives concrete proof points for that claim. Cardiac Ablation Solutions is the clearest milestone. Revenue grew 88% worldwide with U.S. up 139%, Sphere‑9 gained 9 share points in one quarter and the Affera system installed base rose about 35% sequentially. That directly supports the idea of a broader, recurring catheter ecosystem taking hold.

Renal denervation and Altaviva also moved from story to execution. Symplicity Spyral is at roughly US$100m annualized sales and management cites improving reimbursement and hospital interest. Altaviva procedures doubled sequentially. Hugo robotics, Touch Surgery and the Cornerstone Sentire deal show Medtronic building a multi platform robotic and AI surgery stack that can drive future instrument and software pull through, even if the financial impact is still early.

Access the analyst estimates for Medtronic to see where the consensus models start to diverge on Medtronic’s next few fiscal years and whether this seemingly calm 1.5% post earnings move is masking a much sharper inflection point in the projected timeline.

Medtronic Bear Case: Early Wins, Key Tests Still Ahead

Bears worry Medtronic’s new platforms will not scale fast enough to move the needle or sustain margins once early launch buzz fades. This quarter does not fully settle that concern. Cardiac Ablation Solutions and renal denervation hit important adoption markers, yet they still represent a small slice of US$9.8b in quarterly revenue and benefited from an extra selling week that flatters growth optics.

Another bearish worry is that portfolio complexity, M&A, and legal overhangs could sap earnings quality. The Covidien hernia mesh verdict, recent tuck-in deals like SPR Therapeutics and Scientia Vascular, and the Cornerstone Robotics and Pi Cardia options all add integration and execution risk, while Q1 margin expansion was only 10 bps at both gross and operating levels. Guidance for roughly 50 bps operating margin improvement and about 10% operating profit growth sets a bar that still needs to be cleared in later quarters.

Medtronic’s guidance raise and margin stability will only matter for you if the balance sheet and cash generation can comfortably support dividends, product launches and ongoing legal costs. Check the financial health analysis of Medtronic stock to verify whether that cushion looks robust or thin before taking the next step.

Stay Ahead With Medtronic Insights

If Medtronic’s stronger Q1 figures and raised guidance have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for an entry point that fits your plan. Once you own it, use the Portfolio Command Center to cut through market noise and focus on the updates that matter for your holdings. For a longer term view, tap into the Community to see how other investors interpret new data and company developments. By surfacing potential catalysts and risks early, you can make decisions faster and stay a step ahead of the market.

Seeking Alternatives Beyond Medtronic?

Fresh stock ideas can break out fast while attention lingers on familiar names. Use curated screeners to spot momentum before the crowd, while it matters. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.